baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Call 250 BIIB 21.06.2024/ DE000VM4KFE0 /

2024-05-29 10:12:18 AM	Chg.+0.021	Bid12:25:18 PM	Ask12:25:18 PM	Underlying	Strike price	Expiration date	Option type
0.143EUR	+17.21%	0.142 Bid Size: 15,000	0.163 Ask Size: 15,000	Biogen Inc	250.00 USD	2024-06-21	Call

GlobeNewswire 3:00 AM BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Fil...

GlobeNewswire 05-28 BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of U...

GlobeNewswire 05-28 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen...

GlobeNewswire 05-25 BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with ...

GlobeNewswire 05-25 BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Again...

GlobeNewswire 05-25 Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against...

GlobeNewswire 05-24 BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class ...

GlobeNewswire 05-24 BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Sub...

GlobeNewswire 05-23 SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Con...

GlobeNewswire 05-23 Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB...

GlobeNewswire 05-23 BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Sub...

GlobeNewswire 05-22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...

GlobeNewswire 05-21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 05-16 Fortrea Appoints Machelle Sanders to Board of Directors

GlobeNewswire 05-16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 05-15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...

GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...

GlobeNewswire 05-09 Royalty Pharma Reports First Quarter 2024 Results

GlobeNewswire 05-08 IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

GlobeNewswire 05-08 C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 05-02 Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire 04-29 Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...

GlobeNewswire 04-25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...

TeleTrader 04-24 US closes mixed with earnings in limelight

BVT Call 250 BIIB 21.06.2024/ DE000VM4KFE0 /

If you wish to receive reply to your feedback, please provide your email address.